Oklo's cancer-isotope plant lands with no buyer, no price and a $6.5 billion bill

The announcement sets no commercial terms

Oklo▼−1.33% — Oklo, down 1.33 percent today, an advanced nuclear developer whose Aurora power plants have never sold a watt of electricity, said on October 13 that the Department of Energy's National Reactor Innovation Center picked 12 developers across 13 projects for its Nuclear Energy Launch Pad↗, and that Oklo↗'s Groves 2 Forge is among them ¹. Groves 2 Forge is a planned Texas pilot facility to produce, process and purify lutetium-177, an isotope that carries radiation directly to cancer cells ¹. The announcement names no contract value, no customer, no production volume and no federal dollar amount, and it says commercial-scale output requires Nuclear Regulatory Commission licenses Oklo does not yet hold ¹.

The market has already voted

Shares closed at $34.57 on October 8, 80 percent below the highest close of the prior year, at an enterprise value of $3.97 billion, down 75 percent from $15.95 billion in September 2025 ²³. Behind that price sits a bill. Consensus has Oklo burning cash every year through 2030, from about $520 million in 2026 to about $2.7 billion in 2030, which leaves roughly $6.5 billion of funding needs after the $192 million consumed in the first half of 2026 ²³. That is more than twice the $3.0 billion of cash and marketable securities reported at June 30 ²³.

The first isotope revenue points to a different facility

Even the near-term isotope money points away from Groves 2 Forge. Management said on its August earnings call that first isotope revenue is more likely in the first part of 2027, from the Idaho Radiochemistry Laboratory, a facility already licensed by the Nuclear Regulatory Commission, while the Groves test reactor works up toward research quantities ⁴. Oklo's first revenue in company history, about $1.2 million in the quarter ended in June, came mostly from services, not power or isotopes ⁴. The funding route stays equity: about $1.9 billion was raised through at-the-market share sales in the first half, and a fresh $1 billion program was signed on September 11↗ ⁵⁶.

The demand for lutetium-177 is real

Novartis's lutetium-177 prostate-cancer drug Pluvicto sold $651 million in the second quarter↗, up 43 percent in constant currencies, and many critical isotopes still come from aging or foreign facilities ⁷¹. Suppliers are spending to close that gap: the isotope producer NorthStar Medical Technologies just secured up to $185 million from Hercules Capital to expand production and contract manufacturing ⁸. Groves reached criticality in under a year, the first Reactor Pilot Program project on private land to do so ¹. On the power side, Meta▲+2.70% — Meta, up 2.70 percent today Platforms has agreed to support up to 1.2 gigawatts of reactor development in Ohio, prepaying to help fund fuel, and the data-center operator Equinix has paid an advance; neither amount is disclosed ⁴².

What November decides

The third-quarter report, expected in November, is the first place isotope terms could appear ²³. Also open is a definitive agreement with Centrus Energy, the enriched-uranium supplier named in a letter of intent to fuel up to five Aurora powerhouses↗ with deliveries starting in 2029; whether Oklo or its customers pay the fuel prepayments is unresolved ³⁵. Until a lutetium-177 buyer and a price appear, the isotope line changes nothing about who pays for the reactor build-out.